MedTrace Logo

Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients

NCT02400398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-08-11

No results posted yet for this study

Summary

Eligible patients will have a diagnosis of both pancreatic adenocarcinoma and cachexia defined as greater than 5% unintentional weight loss within 6 months prior to screening visit. Patients must be greater than 18 years of age; and have greater than 3 months life expectancy.

This study will observe a standard of care intervention (tube feeding) for potential benefit. Peptamen will be administered through a jejunal or a gastrojejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered daily for the duration of the protocol.

Conditions

Interventions

OTHER

Tube feeding

Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.

Sponsors & Collaborators

  • Andrew Hendifar, MD

    lead OTHER

Principal Investigators

  • Andrew Hendifar, MD · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-27
Primary Completion
2019-03-31
Completion
2020-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02400398 on ClinicalTrials.gov